We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GE Healthcare Launches Xuri™ IL-2 Growth Factor
Product News

GE Healthcare Launches Xuri™ IL-2 Growth Factor

GE Healthcare Launches Xuri™ IL-2 Growth Factor
Product News

GE Healthcare Launches Xuri™ IL-2 Growth Factor


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "GE Healthcare Launches Xuri™ IL-2 Growth Factor"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Xuri™ IL-2 is a dedicated cell therapy ancillary product for the ex vivo cultivation of T-lymphocytes. Xuri IL-2’s defined level of biological activity removes the need for revalidation of each lot and strongly improves reproducibility, thereby minimizing process development time and improving scale out capacity.

Xuri IL-2 features low endotoxin levels (<0.025 EU/µg), is produced under a GMP license certified and regularly audited, quality controlled under ISO9001:2008 and in accordance with the International Conference on Harmonization (ICH) guideline.

Xuri IL-2 is supplied with comprehensive instructions for straightforward expansion in static culture and with the Xuri Cell Expansion Systems W5 and W25.

Also now available is IL-2 for preclinical use, a cost efficient alternative for the cultivation of T-lymphocytes in proof-of-principle and basic research experiments.

The close equivalence between IL-2 and Xuri IL-2 simplifies the transition from research to process development for cell therapy manufacturing with minimized optimization time while supporting regulatory compliance.

Xuri products are supplied with a comprehensive documentation support package that follows USP <1043> requirements applicable to a supplier of ancillary material for cell, gene and tissue-engineered products to enable a full assessment and documentation of the production processes. This contributes significantly to facilitating risk assessment and validation in cell therapy manufacturing.

Advertisement